

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7622835

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MARY KAY INC.	11/01/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ALLUSTRA TECHNOLOGIES LLC
<b>Street Address:</b>	16251 DALLAS PARKWAY
<b>City:</b>	ADDISON
<b>State/Country:</b>	TEXAS
<b>Postal Code:</b>	75001
<b>PROPERTY NUMBERS Total: 11</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	10111828
Patent Number:	9463156
Patent Number:	8758784
Patent Number:	8568752
Patent Number:	8562962
Patent Number:	8273338
Patent Number:	8252274
Patent Number:	8182799
Patent Number:	7425323
Patent Number:	7175837
Patent Number:	6495126
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	pam.gerik@nortonrosefulbright.com
<b>Correspondent Name:</b>	NORTON ROSE FULBRIGHT US LLP
<b>Address Line 1:</b>	98 SAN JACINTO BLVD, SUITE 1100
<b>Address Line 4:</b>	AUSTIN, TEXAS 78701
<b>ATTORNEY DOCKET NUMBER:</b>	ALST.P0001

<b>NAME OF SUBMITTER:</b>	MICHAEL R. KRAWZSENEK
<b>SIGNATURE:</b>	/MICHAEL R. KRAWZSENEK/
<b>DATE SIGNED:</b>	11/02/2022
<b>Total Attachments: 3</b> source=MKAY-TO-ALLUSTRA ASSIGNMENT 3#page1.tif source=MKAY-TO-ALLUSTRA ASSIGNMENT 3#page2.tif source=MKAY-TO-ALLUSTRA ASSIGNMENT 3#page3.tif	

## ASSIGNMENT AGREEMENT

This Assignment Agreement (the "Agreement") is made and entered into on November 1, 2022 (the "Effective Date"), by **Mary Kay Inc.**, a Delaware Limited Liability Company with an address of 16251 Dallas Pkwy, Addison, TX 75001 ("Assignor") and **Allustra Technologies LLC**, a Delaware Limited Liability Company with an address of 16251 Dallas Pkwy, Addison, TX 75001 ("Assignee").

### RECITALS

Assignor is the owner of the United States patent set forth on Exhibit A hereto (the "Patents").

Assignor shall sell, transfer, and assign and set over unto Assignee and Assignee shall accept, all right, title, and interest in and to the Patents as specified in this Agreement.

### AGREEMENT

For good and valuable consideration, the receipt, sufficiency, and adequacy of which are acknowledged, Assignor and Assignee agree as follows:

1. Assignor does hereby sell, transfer, convey, assign, and deliver to Assignee all of Assignor's right, title, and interest in, to, and under the Patents and any reissues or reexaminations of any of the Patents. The right, title, and interest includes, but is not limited to, the right to sue for injunctions, damages, and/or royalties for any past, ongoing, and/or future infringement.
2. Assignor hereby acknowledges and agrees that all of the right, title, and interest in and to the Patents sold, transferred, assigned and set over to Assignee hereunder includes all income, royalties, damages, and payments now or hereafter due or payable with respect thereto, and all causes of action (whether in law or equity) and the right to sue, counterclaim, and recover for the past, present, and future infringement of the rights assigned hereunder.
3. Assignor hereby consents that a copy of this Agreement shall be deemed a full legal and formal equivalent of any assignment, consent to file or like document that may be required for any purpose.
4. Assignee hereby grants to Assignor and its affiliates a fully paid-up, non-exclusive, irrevocable, worldwide license to make, have made, use, import, export, distribute, sell, offer for sale, develop and advertise under the Patents solely with respect to the products and services of Assignor and its affiliates. This license is transferable to any successor or assign of Assignor, and is sublicensable to affiliates, contractors, resellers, dealers, and any third parties designing, manufacturing, selling, repairing or otherwise servicing the goods or services of Assignor.

*Signature Page Follows*

IN WITNESS WHEREOF, the Parties have executed this Assignment on the Effective Date.

Assignor:

**Mary Kay Inc.**

By: 

John D. Wiseman  
VP, Deputy General Counsel &  
Assistant Corporate Secretary, Mary  
Kay Inc.

Assignee:

**Allustra Technologies LLC**

By: 

John D. Wiseman  
President, Allustra Technologies LLC

**EXHIBIT A**

**TO ASSIGNMENT AGREEMENT**

<b>US App Serial Number</b>	<b>US Patent No.</b>	<b>Title</b>
15/284,158	10,111,828	Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation
14/289,416	9,463,156	Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation
14/030,877	8,758,784	Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation
13/852,542	8,568,752	Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation
13/619,677	8,562,962	Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation
12/632,554	8,273,338	Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation
12/202,924	8,252,274	Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation
12/479,079	8,182,799	Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation
11/624,840	7,425,323	Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation
10/273,649	7,175,837	Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation
09/357,288	6,495,126	Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation